Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) has delivered its first Vega systems to Berry Genomics under an early access agreement from 2022. Berry Genomics will develop targeted assays for carrier, prenatal, and newborn screening programs in China and other markets using the Vega platform.
The company will pursue NMPA regulatory review in China and support additional product registrations in other markets. Berry has committed to purchasing over 50 Vega units as part of the agreement.
Vega, PacBio's first benchtop long-read sequencing platform introduced last year, is designed as a compact, lower-throughput version of their Revio™ system. It offers HiFi technology for high accuracy and quick turnaround time, targeting small to medium-sized laboratories that need efficient genomics equipment with a smaller footprint and price tag.
PacBio (NASDAQ: PACB), a leading developer of high-quality sequencing solutions, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 4:30 PM PT (7:30 PM ET) in San Francisco, California.
Interested parties can access a live webcast of the event through PacBio's investors page at investor.pacificbiosciences.com. The presentation recording will remain available for a minimum of 30 days after the event.
PacBio (NASDAQ: PACB), a leading developer of high-quality sequencing solutions, has announced its participation in four major upcoming investor conferences in November and December 2024. The schedule includes appearances at the UBS Global Healthcare Conference in Rancho Palos Verdes, Wolfe Research Healthcare Conference and Piper Sandler Healthcare Conference in New York, and Stephens Annual Investment Conference in Nashville. All presentations will be available via live webcasts on PacBio's investor page, with replays accessible for at least 30 days after each event.
PacBio reported Q3 2024 financial results with revenue of $40.0 million, down from $55.7 million in Q3 2023. Instrument revenue was $16.8 million, including 22 Revio systems sold. The company reported a net loss of $60.7 million ($0.22 per share). Notable developments include the announcement of SPRQ chemistry for Revio, increasing throughput by 33%, and the launch of Vega, a new long-read benchtop sequencer priced at $169,000. Cash position stood at $471.1 million as of September 30, 2024. The company also announced a private convertible note exchange transaction of $459 million.
PacBio announced a private convertible exchange transaction involving $459 million of its 1.50% Convertible Senior Notes due 2028. In exchange, the company will issue $200 million in new 1.50% Convertible Senior Notes due 2029, issue 20,451,570 shares of common stock, and make a $50 million cash payment. The new notes will have an initial conversion rate of 204.5157 shares per $1,000 principal amount, equivalent to approximately $4.89 per share. The transaction is expected to close around November 21, 2024, and will result in no remaining 2028 Notes outstanding.
PacBio (NASDAQ: PACB) has announced the Vega™ system, its first benchtop long-read sequencing platform, priced at $169,000. The system delivers the functionality of the Revio system in a compact, lower-throughput format. Vega offers HiFi technology for accurate sequencing across various applications, including targeted sequencing, RNA sequencing, and small genome sequencing. The system can process 600 full-length RNA samples per year, 9,600 samples using the PureTarget repeat expansion panel, or 200 human genomes. Shipping is planned to begin in Q1 2025.
Volta Labs has joined the PacBio Compatible program, strengthening their partnership to provide automated library preparation solutions for PacBio sequencing customers. The collaboration centers on the Callisto Sample Prep System, which enables automated preparation of PacBio HiFi libraries with minimal hands-on time (less than 30 minutes) and 5.5 hours of walk-away time. The system supports batch sizes from 4-24 reactions and offers high yield at half-scale reactions. Recent data presented at a Genomeweb webinar demonstrated the system's impact on scaling PacBio sequencing operations, particularly benefiting organizations from core labs to biotech companies.
PacBio has announced SPRQ, a new sequencing chemistry for its Revio long-read sequencing system that brings significant improvements. The update reduces DNA input requirements by 4x to 500ng per sample and increases data output by 33% per SMRT Cell. These enhancements enable sequencing costs to drop below $500 per human genome, with each Revio system capable of sequencing up to 2,500 human genomes annually. The upgrade also improves methylation calling accuracy and adds new methylation mark detection capabilities, providing enhanced multiomic analysis. The SPRQ chemistry will be compatible with all existing Revio systems through a simple software update, with shipping beginning in December 2024.
PacBio (Nasdaq: PACB) has announced the inclusion of its Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. This program recognizes instruments and workflows compatible with 10x Genomics' products and applications, expanding sequencing solutions for researchers worldwide.
The Onso platform, known for its exceptional accuracy in short-read sequencing, aligns well with 10x Genomics' tools for single-cell and spatial biology applications. It joins PacBio's MAS-seq long read RNA sequencing solution in the program, as part of PacBio's effort to provide integrated workflows for genomics and transcriptomics research.
Key benefits of this collaboration include:
- Streamlined workflows combining PacBio's Onso platform with 10x Genomics' technologies
- Compatibility with 10x Genomics' Single Cell 3' v3.1 assay
- Enhanced data quality and efficiency in research
- Unmatched sequencing accuracy from PacBio's Onso platform
PacBio (NASDAQ: PACB) has announced a Research Collaboration Agreement with the National Cancer Centre of Singapore (NCCS) to accelerate cancer research using PacBio's advanced sequencing technologies. The collaboration will focus on profiling prevalent cancers in Asia using the Onso short-read sequencing system and Kinnex long-read sequencing kit, with emphasis on single-cell RNA sequencing.
The Onso platform, known for its exceptional accuracy, will be used to detect clinically relevant mutations across various cancer types. PacBio's authorized channel partner, DKSH, has installed the Onso platform at the Cancer Discovery Hub in NCCS. This collaboration aims to benefit Singapore and provide access to cutting-edge technology for the broader research community in Asia.
The integration of Onso for short reads and Revio for long reads will enable comprehensive multi-omics studies, offering new possibilities for precision oncology. This initiative combines short-read and long-read sequencing to explore the genomic complexities of cancers prevalent in Asia, with the ultimate goal of improving tailored diagnostic and treatment options for patients.